Lutris Pharma appoints Mori Arkin to its Board of Directors

– ISRAEL, Tel Aviv –  Lutris Pharma, a clinical-stage biopharmaceutical company focused on improving anti-cancer therapies by reducing dose-limiting side effects, announced the appointment of Mori Arkin to its Board of Directors.

About Moshe “Mori” Arkin

Mori Arkin founded Arkin Holdings in 2009 and today owns a healthcare portfolio worth $1.5 billion through five investment arms, with holdings in some 20 Israeli companies developing pharmaceutical drugs and equipment. Previously Mr. Arkin headed Agis Industries Ltd., which he took over at age 19 from his late father, Ziama Arkin, and which he successfully grew into a leading dermatological company in the U.S. until its acquisition by Perrigo in 2005 for $818 million. He has extensive experience in developing and commercializing pharmaceutical drug products and has held leadership roles in several companies with significant ties to innovative and generic drug companies.

Mori Arkin said, “I look forward to working more closely with Lutris Pharma’s management team and Board as we work to fulfill our mission to improve anti-cancer therapy effectiveness, as well as the quality of life for patients who develop EGFR inhibitor-induced acneiform lesions or radiation-induced dermatitis.”

Mr. Arkin holds an undergraduate degree in psychology and philosophy from Tel Aviv University and has studied for several years at the university’s Cohn Institute for the History and Philosophy of Science and Ideas.

Together with his wife Doris, Mr. Arkin has been involved in a broad range of social and cultural philanthropic ventures in Israel. In 2011, they formed the Arkin Family Foundation, which supports organizations and projects in education, arts and culture, welfare, healthcare, civil rights, and Jewish-Arab coexistence.

About Lutris Pharma

Lutris Pharma is a clinical-stage biopharmaceutical company focused on improving anti-cancer therapy effectiveness and quality of life for patients who are being treated with EGFR (Epidermal Growth Factor Receptor) inhibitors or with radiation, where dermal toxicity often leads to a reduction of anti-cancer therapy compliance. The company aims to provide novel topical therapies to mitigate these side effects. Lutris Pharma’s lead asset, LUT014, a topical B-Raf Inhibitor, is a proprietary, first-in-class, small molecule currently in phase 2 clinical trial in metastatic colorectal cancer patients with EGFR inhibitor-induced acneiform lesions and has completed a phase 1/2 study for the treatment of radiation-induced dermatitis in breast cancer patients.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.